BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab operating margin
Operating margin is operating income as a percentage of revenue.
BioNexus Gene Lab's operating margin for the twelve months ending Jun 30, 2026 was -81.8%. For fiscal 2025 it was -39.9%, against -16.5% the year before. The highest annual figure on record is 28.2% in fiscal 2018.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -39.9% | −23.4 |
| FY2024 | Dec 31, 2024 | -16.5% | +10.0 |
| FY2023 | Dec 31, 2023 | -26.5% | −23.9 |
| FY2022 | Dec 31, 2022 | -2.7% | −10.6 |
| FY2021 | Dec 31, 2021 | 7.9% | −3.3 |
| FY2020 | Dec 31, 2020 | 11.2% | +228.4 |
| FY2019 | Dec 31, 2019 | -217.2% | −245.4 |
| FY2018 | Dec 31, 2018 | 28.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -370.8% | −343.8 |
| Q1 FY2026 | Mar 31, 2026 | -2366.2% | −2337.3 |
| Q4 FY2025 | Dec 31, 2025 | -213.5% | −197.0 |
| Q3 FY2025 | Sep 30, 2025 | -27.6% | +23.2 |
| Q2 FY2025 | Jun 30, 2025 | -27.0% | −40.2 |
| Q1 FY2025 | Mar 31, 2025 | -28.9% | −25.6 |
| Q4 FY2024 | Dec 31, 2024 | -16.5% | −27.8 |
| Q3 FY2024 | Sep 30, 2024 | -50.9% | +48.2 |
| Q2 FY2024 | Jun 30, 2024 | 13.1% | +23.7 |
| Q1 FY2024 | Mar 31, 2024 | -3.3% | −1.2 |
| Q4 FY2023 | Dec 31, 2023 | 11.3% | +15.7 |
| Q3 FY2023 | Sep 30, 2023 | -99.0% | −96.5 |
| Q2 FY2023 | Jun 30, 2023 | -10.6% | −5.1 |
| Q1 FY2023 | Mar 31, 2023 | -2.1% | −3.3 |
| Q4 FY2022 | Dec 31, 2022 | -4.3% | −10.5 |
| Q3 FY2022 | Sep 30, 2022 | -2.5% | −13.0 |
| Q2 FY2022 | Jun 30, 2022 | -5.6% | −10.1 |
| Q1 FY2022 | Mar 31, 2022 | 1.1% | −8.8 |
| Q4 FY2021 | Dec 31, 2021 | 6.2% | +6.3 |
| Q3 FY2021 | Sep 30, 2021 | 10.4% | +2.7 |
| Q2 FY2021 | Jun 30, 2021 | 4.5% | +7.6 |
| Q1 FY2021 | Mar 31, 2021 | 9.9% | −25.0 |
| Q4 FY2020 | Dec 31, 2020 | -0.1% | +181.2 |
| Q3 FY2020 | Sep 30, 2020 | 7.7% | +215.1 |
| Q2 FY2020 | Jun 30, 2020 | -3.1% | +316.7 |
| Q1 FY2020 | Mar 31, 2020 | 35.0% | +249.3 |
| Q4 FY2019 | Dec 31, 2019 | -181.2% | +492.2 |
| Q3 FY2019 | Sep 30, 2019 | -207.4% | −147.2 |
| Q2 FY2019 | Jun 30, 2019 | -319.8% | −284.3 |
| Q1 FY2019 | Mar 31, 2019 | -214.3% | – |
| Q4 FY2018 | Dec 31, 2018 | -673.4% | – |
| Q3 FY2018 | Sep 30, 2018 | -60.2% | – |
| Q2 FY2018 | Jun 30, 2018 | -35.5% | – |
See a number that looks wrong?